Metabolic syndrome and C-reactive protein in the general population - JMS cohort study

Circulation Journal

Volumn 71, Issue 1, 2007, Pages 26-31

  Ishikawa, Shizukiyo ^a   Kayaba, Kazunori ^b   Gotoh, Tadao ^a   Nakamura, Yosikazu ^a   Kajii, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SAITAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; Cardiovascular diseases; General population; Japanese; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; JAPAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEPHELOMETRY; POPULATION DISTRIBUTION; POPULATION RESEARCH; PROTEIN ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33845997475     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.26     Document Type: Article

References (38)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
2. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004; 53: 1068-1073.
3. Hillier TA, Rizzo JH, Pedula KL, Cauley JA, Schwartz AV, Ensrud KE, et al. Increased mortality associated with the metabolic syndrome in older women with diabetes. Diabetes Care 2005; 28: 2258-2260.
4. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-673.
5. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109: 706-713.
6. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. In: Report of a WHO consultation. Geneva: WHO; 1999.
7. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Nippon Naika Gakkai Zasshi 2005; 94: 794-809 (in Japnaese).
9. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
10. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
11. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins: A population-based study. Eur Heart J 1999; 20: 954-959.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
13. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-842.
14. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-2021.
15. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
16. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003; 27: 443-449.
17. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97: 101-106.
18. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.
19. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005; 28: 878-881.
20. Oda E, Oohara K, Abe A, Veeraveedu PT, Watanabe K, Kato K, et al. The optimal cut-off point of C-reactive protein as an optional component of metabolic syndrome in Japan. Circ J 2006; 70: 384-388.
21. Ishikawa S, Gotoh T, Nago N, Kayaba K. The Jichi Medical School (JMS) Cohort Study: Design, baseline data and standardized mortality ratios. J Epidemiol 2002; 12: 408-417.
22. Kannel WB, Sorlie P. Some health benefits of physical activity: The Framingham Study. Arch Intern Med 1979; 139: 857-861.
23. Itoh Y, Ichihara K, Kanno T, Sugawara T, Ohkubo A, Hirabayashi Y, et al. serum protein standardization project in Japan: Evaluation of an IFCC reference material (RPPHS/CRM470) and establishment of reference intervals. J Clin Lab Anal 1997; 11: 39-44.
24. Oda E, Watanabe K. Japanese criteria of metabolic syndrome. Circ J 2006; 70: 364.
25. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study. Stroke 2001; 32: 2575-2579.
26. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-547.
27. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999; 100: 96-102.
28. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183-1190.
29. Kayaba K, Tsutsumi A, Gotoh T, Ishikawa S, Miura Y. Five-year stability of job characteristics scale scores among a Japanese working population. J Epidemiol 2005; 15: 228-234.
30. Sone H, Tanaka S, Ishibashi S, Yamasaki Y, Oikawa S, Ito H, et al. The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions: Additional analysis from the Japan Diabetes Complications Study. Diabetes Care 2006; 29: 145-147.
31. Kawamoto R, Tomita H, Oka Y, Kodama A. Metabolic syndrome as a predictor of ischemic stroke in elderly persons. Intern Med 2005; 44: 922-927.
32. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
33. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167-2176.
34. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004; 109: 3022-3028.
35. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-1410.
36. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: The Minoh Study. Circ J 2005; 69: 386-391.
37. Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, et al. Metabolic syndrome and cardiac disease in Japanese men: Applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men: The Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203-208.
38. Miyatake N, Kawasaki Y, Nishikawa H, Takenami S, Numata T. Prevalence of metabolic syndrome in Okayama prefecture, Japan. Intern Med 2006; 45: 107-108.